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Marc R. Friedländer 2, Domenico Accili 1,*ABSTRACT
Objectives: Hepatic insulin resistance is a hallmark of type 2 diabetes and obesity. Insulin receptor signaling through AKT and FOXO has
important metabolic effects that have traditionally been ascribed to regulation of gene expression. However, whether all the metabolic effects of
FOXO arise from its regulation of protein-encoding mRNAs is unknown.
Methods: To address this question, we obtained expression proﬁles of FOXO-regulated murine hepatic microRNAs (miRNAs) during fasting and
refeeding using mice lacking Foxo1, 3a, and 4 in liver (L-Foxo1,3a, 4).
Results: Out of 439 miRNA analyzed, 175 were differentially expressed in Foxo knockouts. Their functions were associated with insulin, Wnt,
Mapk signaling, and aging. Among them, we report a striking increase of miR-205-5p expression in L-Foxo1,3a,4 knockouts, as well as in obese
mice. We show that miR-205-5p gain-of-function increases AKT phosphorylation and decreases SHIP2 in primary hepatocytes, resulting in FOXO
inhibition. This results in decreased hepatocyte glucose production. Consistent with these observations, miR-205-5p gain-of-function in mice
lowered glucose levels and improved pyruvate tolerance.
Conclusions: These ﬁndings reveal a homeostatic miRNA loop regulating insulin signaling, with potential implications for in vivo glucose
metabolism.
 2018 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Insulin resistance predisposes to diabetes and obesity [1]. The pleio-
tropic effects of insulin are partly mediated by the PI3K/AKT/FOXO1
pathway [1e3]. In liver, insulin decreases glucose production and
increases glucose utilization by inhibiting FOXO, whereas insulin
resistance activates FOXO, contributing to hyperglycemia and hyper-
triglyceridemia [4,5]. The protein-coding target genes of FOXO have
been studied in detail [6e8]. However, little is known about FOXO
regulation of gene expression through micro-RNA (miRNA)-mediated
gene silencing.
miRNAs regulate gene expression in physiologic and disease condi-
tions, including insulin-resistant diabetes [9,10]. Interestingly,
genome-wide association studies for type 2 diabetes susceptibility loci
indicate that most of the diabetes-associated variants localize to non-
coding regions [11,12], raising the possibility that miRNAs transcribed
from these regions contribute to disease development. Several hepatic
miRNAs, including miR-33 [13], miR-122 [14], miR103/107 [15], and
miR-802 [16] have been shown to post-transcriptionally control
expression of genes involved in metabolism and insulin signaling.1Naomi Berrie Diabetes Center and Departments of Medicine, Columbia University, N
sciences, The Wenner-Gren Institute, Stockholm University, 17121, Stockholm, Swed
Columbia University, New York, 10032, USA 4Department of Clinical and Experimental
Physiology, Pisa, Italy
6 Present address: Center for Integrative Genomics, University of Lausanne, 1015, La
*Corresponding author. Naomi Berrie Diabetes Center, 1150 St Nicholas Ave, New Yo
Received July 28, 2018  Accepted August 7, 2018  Available online 11 August 201
https://doi.org/10.1016/j.molmet.2018.08.003
MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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search for FOXO-regulated hepatic miRNAs and investigated their
metabolic role. Using miRNA proﬁling of FOXO-deﬁcient mice, we
catalogued FOXO-modulated miRNAs and identiﬁed miR-205-5p as an
endogenous regulator of insulin sensitivity that coordinately targets
components of the insulin signaling cascade.
2. MATERIAL AND METHODS
2.1. Experimental model and subject details
2.1.1. Mice
Male mice (9-24-week-old) were maintained on chow (PicoLab rodent
diet 20, 5053; Purina Mills). All experiments were approved by
Columbia University Institutional Animal Care and Use Committee.
L-Foxo1, L-Foxo1,3a,4, db/db, ob/ob, and Sin3alox/lox:Sin3blox/lox
[3,4,6,17] and iL-Sin3a/3b mice have been described [6]. C57Bl6, ob/
ob, db/db, and 10-week DIO mice were from The Jackson Labora-
tories. To overexpress miR-205-5p, we injected 1  1011 particles
(AAV8.TBG.miRNA (Scramble)-CMV-GFP or AAV8.TBG.miR-205-5p-ew York, 10032, USA 2Science for Life Laboratory, Department of Molecular Bio-
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Original ArticleCMV-GFP) in C57Bl6J, and killed the animals after 25 days. For miR-
205-5p knock down, C57Bl6J mice were fed high-fat diet for 10 weeks
(DIO) (OpenSource Diets, Cat#: D12492), and injected with Custom
miRCURY LNA (Exiqon, hsa-miR-205-5p) (Batch nb: 681392) or control
(Batch nb: 681393) (15 mg/kg) for 3 days, and killed after 25 days.
For miRNA sequencing and miR-205 gain-of-function, L-Foxo1,3a,4
and C57Bl6J mice were fasted overnight and refed (or not) for 4-hr. For
miR-205 loss-of-function, DIO mice were fasted for 5 h. For qPCR, L-
Foxo1, L-Foxo1,3a,4 and iL-Sin3a/3b mice were fasted overnight; ob/
ob, db/db and DIO mice for 5 h.
2.1.2. Primary hepatocyte culture
Primary hepatocytes were isolated and transfected with plasmids (500
ng/5  105 cells, 48-hr) using Lipofectamine2000 as described [18].
miR-205-5p was overexpressed with miRCURY LNA miRNA Mimics
(15e50nM/5  105 cells, 48-hr) against murine miR-205-5p; cel-39-
3p was used as control. Cells were incubated with 100 uM 8-CPT-
cAMP, 1 uM dex, 100 nM insulin or vehicle for 7-hr.
2.1.3. Human studies
Liver biopsies were obtained during bariatric surgery in 10 type 2
diabetics and 10 nondiabetics [19,20]. We extracted RNA with RNA-
Later (Ambion Inc., Applied Biosystems, Austin, TX, USA) and ob-
tained plasma samples after an overnight fast. Diabetic patients dis-
continued treatment 48e72 h before the study. The protocol was
approved by the University of Pisa IRB. The nature and purpose of the
study were carefully explained to all participants before they provided
written consent to participate.
2.2. Method details
2.2.1. Chemicals and antibodies
Reagents were from the following manufacturers: ketamine
(KetaSet), Xylazine (AnaSed), Medium 199, HBSS, EGTA, HEPES,
PenStrep and Gentamycin (Life Technology), Collagen 4 (Worthington),
Humulin R U-100 (Lilly), 8-(4-chlorophenylthio) (CPT)-cAMP, dexa-
methasone, cycloheximide, bovine serum albumin, D-glucose and
sodium pyruvate (SigmaeAldrich), Lipofectamine2000 (Thermo
Fisher), miRCURY LNA (Qiagen) (biotinylated mmu-205-5p and cel-39-
3p), anti-FOXO1 (C29H4, # 2880S), anti-Phospho-FoxO1 (Thr24)/
FoxO3a (Thr32) (#2599S), anti-Akt, anti-Phospho-Akt (Ser473) (D9E,
#4060), anti-SHIP2 (#3397S) and anti-PTEN (#9188S) (Cell Signaling),
anti-actin (ab8227) (Abcam).
2.2.2. Plasmids/Viruses
RFP (CTL) and FOXO1 plasmids have been described [21]. Plasmids
encoding miTarget 30UTR miRNA Target Clones were from Gene-
Copoeia (CTRL: CmiT000001-MT05, and FOXO1: Mmi7055419-
MT05); AAV8.TBG.eGFP and AAV8.TBG.Cre from Penn Vector Core;
AAV8.TBG.miRNA (Scramble)-CMV-GFP and AAV8.TBG.miR-205-5p-
CMV-GFP from SignaGene.
2.2.3. RNA and miRNA studies
For qPCR, we used RNeasy kit (Qiagen), GoScript (Promega), and
GoTaq qPCR Master Mix (Promega). Gene expression levels were
normalized to TATA-binding protein (TBP) using the 2DDCt method
and are presented as relative transcript levels. For miRNA studies, we
isolated RNA with Mirvana (Thermo Fisher, AM1560) or Trizol (Life
Technologies). For miRNA sequencing, total RNA was quantiﬁed with
Ribogreen and libraries were prepared with TruSeq (Illumina, San50 MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. TDiego, CA), quantiﬁed with Agilent 2100 Bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA) HighSensitivity kit, and sequenced on Illu-
mina HiSeq 2500 Rapid single end 50 cycle ﬂow cell. Low quality tags
were altered with FASTX-Toolkit (http://hannon-lab.cshl.edu/fastx_
toolkit/). Reads were processed with the pipeline miraligner and
mapped to miRBase v.20. For miRNA qPCR, we used miScript II RT Kit
(Qiagen) and miScript SYBR Green PCR Kit (Qiagen). Primer assays
were from Qiagen. SNORD61 was used to normalize miRNA levels
using the 2DDCt method.
2.2.4. Protein analysis
We extracted proteins in lysis buffer (20 mM Tris-HCl (pH ¼ 7.4),
150 mM NaCl, 10% glycerol, 2% NP-40, 1 mM EDTA, 20 mM NaF,
30 mM Na4P2O7, 0.2% SDS, 0.5% sodium deoxycholate) with Pro-
tease/Phosphatase Inhibitor Cocktail (1X, Cell Signaling) and used
0.15 mg in SDS buffer for western blot. We used ImageJ (National
Institutes of Health) for densitometry.
2.2.5. Luciferase assays
We transfected hepatocytes with Plasmids encoding miTarget 30UTR
miRNA Target Clones (1ug/5  105 cells), or miRNA mimics (50 nM),
using Lipofectamine 2000 (Invitrogen). 48-hr after transfection, we
assayed luciferase with Secrete-Pair Dual Luminescence Assay Kit
(GeneCopoeia) in an Orion L Microplate Luminometer (Berthold).
2.2.6. Metabolic studies
Glucose production and lipogenesis in primary hepatocyte cultures
have been described [18]. We performed glucose and pyruvate
tolerance tests in 9e15-week-old male mice after a 16-hr fast using
2 g glucose or pyruvate/kg, and insulin tolerance tests after a 5-hr fast
using 0.6 U insulin/kg. Hepatic triglycerides, cholesterol [22], and
glycogen were measured as described [5]. We measured glucose with
OneTouch (One Touch Ultra, Bayer), triglyceride (Inﬁnity, #TR22421,
ThermoFisher), cholesterol (Cholesterol E, #439e17501, Wako Pure
chemicals), and NEFA (HR Series NEFA-HR (2), #999e34691, #995e
34791, #991e34891, #993e35191, Wako Pure chemicals) by
colorimetric assays.
2.2.7. Statistics
Statistical analyses were performed with Prism 5.0 software (Graph
Pad). We used two-tailed Student’s t-test (two groups), one-way
ANOVA followed by Tukey’s multiple comparisons (three or more
groups), and two-way ANOVA followed by Bonferroni correction
(different variables). * ¼ p < 0.05, ** ¼ p < 0.01, *** ¼ p < 0.001.
Results are presented as means  SEM.
3. RESULTS
3.1. FOXOs regulate hepatic miRNA expression
To identify hepatic miRNAs regulated by FOXOs, we sequenced miRNA
from liver of wild type (WT) and liver-speciﬁc Foxo1, 3a, and 4 (L-
Foxo1,3a,4) knockout mice following 12-hr fasting and 4-hr refeeding.
FOXOs are active in the fasted state and are inhibited in the refed state
through insulin-induced Akt-dependent phosphorylation [23]. Out of
1,289 miRNAs found, we analyzed 439 that were detectable in all
samples from fasted and refed mice corresponding tow34% of total.
We detected 109 miRNAs whose expression changed signiﬁcantly
(p< 0.05) in fasted vs. refed mice, irrespective of genotype (Table S1).
Of these, w57% increased and w43% decreased. This analysis
identiﬁed miRNAs known to be regulated by fasting vs. refeeding inhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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liver, such as let-7d, miR-140, miR-210 or miR-22 [24]. When we
compared L-Foxo1,3a,4 and WT mice, irrespective of the feeding state,
we found 175 differentially expressed miRNAs (p < 0.05) (Table S2).
Of these, w43% increased and w57% decreased. This analysis
detected miRNAs associated with insulin sensitivity [e.g., miR-26a
[25], miR-155 [26] and miR-181 [27,28]], gluconeogenesis [e.g.,
miR-22 [29] and miR-29a [30]], or FOXO1 regulation [e.g., miR-122]
[31].
Next, we analyzed differences in fasting vs. refeeding expression ac-
cording to genotype. We detected 52 miRNAs modulated by feeding in
WT and 45 in L-Foxo1,3a,4 (Tables S3 and S4). Of these, 21 were
modulated in both genotypes and in the same direction (Figure 1A,
Table S5). When we analyzed differences between WT and L-
Foxo1,3a,4 according to the feeding state, we detected 92 miRNAs
signiﬁcantly modulated by genotype during fast and 82 after refeeding
(Tables S6 and S7). Of these, 53 were modulated in both conditions
and in the same direction (Figure 1B, Table S5). The conclusion fromFigure 1: FOXOs modulate hepatic miRNA. A-B, Venn diagrams summarizing differentia
L-Foxo1,3a,4 mice (n ¼ 5 per group). C, Heat map of miRNA expression from fasted and re
(RPM) in fasted WT vs. L- Foxo1,3a,4 mice.
MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comthese data is that L-Foxo1,3a,4 mice fail to regulate expression of a
subset of miRNAs in response to fasting and refeeding. Those differ-
ences are more pronounced in the fasted state, when FOXOs are
active. Finally, we performed a four-way comparison among animals of
different genotype (WT vs. L-Foxo1,3a,4 mice) and metabolic state
(fasting vs. refeeding) (Tables S5 and S8). We found 50 miRNAs
regulated by both genotype and metabolic state: 16 increased in L-
Foxo1,3a,4 mice and during refeeding, suggesting that physiologically
they are inhibited by FOXOs; in contrast, 24 decreased in L-Foxo1,3a,4
mice or during refeeding, indicating that they are induced by FOXOs.
10 miRNA changed in opposite directions in L-Foxo1,3a,4 mice and
during refeeding. Among FOXOs-inhibited miRNA, expression of the
miR-96/miR-182/miR-183 cluster increased 3-fold in L-Foxo1,3a,4
mice. As these miRNAs repress FOXO1 [32], the data provide evidence
of feedback regulation of FOXO1 activity. The mir-10 family is inhibited
by FOXOs, whereas miR-30, miR-29 and members of the let-7 family
are induced by FOXOs (Table S8).lly expressed miRNAs (A) between fasted and refed conditions and (B) between WT and
fed WT and L-Foxo1,3a,4 mice. D, Scatterplot of miRNA expression in reads per million
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 51
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signaling
Next, we built a heat map comparing differentially expressed miRNAs
in WT vs. L-Foxo1,3a,4 mice in fasted and refed conditions using a 5%
false discovery rate, and performed hierarchical clustering (Figure 1C).
We detected four clusters: clusters 1 and 2 included miRNA whose
expression was not regulated by fasting or refeeding but increased in
L-Foxo1,3a, 4 mice to a greater (cluster 1) or lesser extent (cluster 2);
clusters 3 and 4 included miRNA regulated in the fasted vs. fed state
whose levels increased (cluster 3) or decreased (cluster 4) in L-
Foxo1,3a,4mice. The conclusion from these data is that FOXO are able
to both induce and inhibit miRNA expression, as they do for gene
expression [6]. Moreover, the observation that regulation by FOXO
seemingly trumps regulation by the feeding state for clusters 1e2,
suggests that the effects of FOXO on miRNA expression can be direct
and indirect.
Next, we generated scatterplots of individual miRNAs as a function of
their levels in fasted WT vs. L-Foxo1,3a,4 mice (Figure 1D). From this
analysis, we selected miRNAs expressed at levels>5 reads per million
that showed a signiﬁcant (p< 0.05) log2-transformed fold-change1
or e1. Among miRNAs thus selected, 9 were decreased, and 7
increased in L-Foxo1,3a,4 mice. Gene ontology (GO) analysis and
perusal of relevant knockout mouse phenotypes (Tables S9 and S10)Figure 2: Hepatic miRNA-205 expression in mice and humans. A-B, miR-205-5p exp
respectively) measured by qPCR. C, miR-205-5p expression in primary hepatocytes from
insulin (n ¼ 4 per group). D-G, miR-205-5p expression in liver of WT vs. iL-Sin3a/b (D) (n
WT vs. ob/ob mice (F) (n ¼ 5 per group), WT vs. hyperinsulinemic db/db (inshigh) (G, n ¼
52 MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. Tidentiﬁed 3 regulators of Wnt signaling (miR-200b, miR-182 and miR-
149) among the FOXO-dependent miRNAs [33,34]. In addition,
pathway analysis highlighted insulin signaling, MAPK signaling, and
aging/lifespan as targets of these miRNAs, consistent with FOXO-
dependent functions [4,35]. The implication of these ﬁndings is that
physiologically relevant FOXO functions can be mediated through
miRNA.
3.3. Pathophysiological regulation of miR-205-5p
Mmu-miR-205-5p topped the list of over-represented miRNAs in
fasted L-Foxo1,3a,4 mice, suggesting that FOXO suppresses its
expression (Table S2, Figure S1A). Ontology analysis suggests that
miR-205-5p increases P3K/Akt signaling (Table S9). Thus, we selected
it for further investigation. Hepatic mmu-miR-205-5p levels are low
and don’t change with fasting and refeeding in WT mice (Figure S1A).
In contrast, in L-Foxo1,3a,4 mice we observed a 15- to 18-fold in-
crease by RNAseq (Figure S1A) and qRT-PCR (Figure 2A) during
fasting, and an w80% decrease upon refeeding (Figure S1A), indi-
cating that FOXOs suppress hepatic miR-205-5p during fasting.
Interestingly, we only saw a 2-fold increase in single knockout L-Foxo1
mice (Figure 2B), suggesting that the large increase in L-Foxo1,3a,4
mice is likely due to FOXO3 (FOXO4 levels being very low), or that the
three isoforms can compensate for each other. In primary hepatocytesression in liver of WT vs. L-Foxo1,3a,4 (n ¼ 5 per group) and L-Foxo1 (n ¼ 7 and 9,
control WT or L-Foxo1 mice after 7-hr treatment with vehicle, cAMP/dex, cAMP/dex/
¼ 6 and 7, respectively), chow vs. diet-induced obese (DIO) mice (E), n ¼ 5 per group),
7/4, respectively). Data are means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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from L-Foxo1 mice, mmu-miR-205-5p increased 2-fold (Figure 2C),
and the increase was partly reversed by transfecting FOXO1
(Figure S1B). Moreover, mmu-miR-205-5p was not regulated by
cAMP/dexamethasone or insulin in primary hepatocytes from L-Foxo1
mice (Figure 2C), failing to mimic the effect of fasting and refeeding.
This suggests either that the regulation is lost during hepatocyte
culture or that indirect mechanisms mediate miR-205 inhibition by
FOXOs in vivo.
Mmu-miR-205-5p localizes to chromosome 1 in mice (193, 507,
463e193,507,530 [-]) and humans (209, 605, 478e209,605,587
[þ]). Analyses of potential regulatory regions of miR-205-5p in the
murine (GRCm38/mm10) and human (GRCh37/hg19) genomes iden-
tiﬁed several potential FOXO binding sites. However, we failed to detect
FOXO binding near miR-205-5p, or in the 5 kb upstream (human
chr1:209, 600, 400e209, 609, 275, GRCh37/hg19) by chromatin
immunoprecipitation. Interestingly, in these assays we detected the
FOXO1 co-repressor, Sin3a [6].
To study the impact of Sin3a (and its closely related homolog Sin3b)
deletion on mmu-miR-205-5p, we deleted Sin3a and Sin3b in adult
mouse liver by injecting AAV8-TBG-CRE in 8-week-old Sin3a lox/lox:-
Sin3b
lox/lox
mice (iL-Sin3a/b mice) [6]. We detected no changes in miR-
205-5p in overnight-fasted iL-Sin3a/b compared to WT mice
(Figure 2D). The failure of FOXO to bind candidate regulatory regions of
the miR-205 gene, and the lack of miR-205-5p variations in iL-Sin3a/b
mice, or of regulation by fasting vs. refeeding (in vivo) or by cAMP/dex
vs. insulin (in vitro) suggest that miR-205-5p is regulated by FOXO
indirectly, probably through the inhibition of a potential miR-205
activator.
Given its potential role in insulin signaling, we analyzed regulation of
miR-205-5p in obesity, insulin resistance, and type 2 diabetes. In diet-
induced obese (DIO), ob/obC57J/B6 and hyperinsulinemic db/db mice
with incipient hyperglycemia (w200 mg/dl) (Figure 2E,F and G,
respectively), miR-205-5p increased after a 5-hr fast compared to
controls. This is consistent with previous reports showing that hepatic
miR-205-5p increases in diabetes-resistant, but not in diabetes-
susceptible mice [36].
3.4. Mmu-miR-205-5p inhibits FOXO1 expression and enhances
insulin signaling
Given its potential role in PI3k/Akt signaling [37e39], we analyzed the
impact of miR-205-5p overexpression on insulin signaling by trans-
fecting primary mouse hepatocytes with miR-205-5p mimics. Over-
expression on miR-205-5p in hepatocytes increased basal AKT
phosphorylation, without changing protein levels. This effect was
blunted by cAMP/dex (Figure 3AeC). The increase in AKT phosphor-
ylation was associated with increased FOXO1 phosphorylation on T24
(Figure 3A,D). miR-205-5p activates PI3K/AKT by targeting PIP3
phosphatases Pten [37] and Ship2 [40]. In primary hepatocytes, miR-
205-5p overexpression decreased Ship2 and increased Phlpp2
(Figure 3E) but had no effect on Pten. Analysis of protein levels by
western blot conﬁrmed these data (Figure 3FeH). These results
indicate that miR-205-5p enhances insulin signaling in vitro.
Moreover, we observed that overexpression of miR-205-5p in primary
hepatocytes decreased FOXO1 protein levels in vehicle- and cAMP/
Dexamethasone-treated conditions (Figure 3A,I). To validate Foxo1
inhibition by mmu-miR-205-5p, we analyzed Foxo1 mRNA in primary
hepatocytes transfected with mmu-miR-205-5p and found it to be
decreased (Figure 3J, Table S11). miRNAs regulate gene expression
through their 50seed region. Base-pairing of the seed sequence to the
target mRNA, usually in the 30-UTR, leads to its repression. Using
TargetScan to predict miRNAs targets [41], we found two potentialMOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. This is an open ac
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coding sequence of Foxo1. To determine if miR-205-5p targets the
Foxo1 30UTR, we used luciferase reporter assays (Figure 3K).
Following miR-205-5p transfection, luciferase activity decreased,
consistent with the possibility that mmu-miR-205-5p targets the Foxo1
30 UTR (Figure 3K). These results suggest that mmu-miR-205-5p acts
in a dual fashion on FOXO1 by increasing Akt-dependent phosphory-
lation and by inhibiting Foxo1 expression (Figure 4). These data are
consistent with reciprocal inhibition by miR-205-5p and FOXO1.
3.5. miR-205-5p, hepatic glucose production, and de novo
lipogenesis
As miR-205-5p increases insulin signaling in vitro, we analyzed its
impact on hepatic glucose production and de novo lipogenesis. We
found that miR-205-5p overexpression decreased cAMP/dex-induced
hepatic glucose production without affecting its inhibition by insulin
(Figure 5A), phenocopying L-Foxo1,3a,4 mice [42]. In contrast to re-
ports in the literature [43], miR-205-5p had no effect on de novo
lipogenesis (Figure 5B), showing a dissociation between effects on
hepatic glucose production and lipogenesis. Moreover, the effect of
miR-205-5p to decrease glucose production was dose-dependent,
plateauing at 30 nM (Figure 5C).
To understand how miR-205-5p decreases hepatic glucose produc-
tion, we analyzed gene expression in primary hepatocytes transfected
with miR-205-5p mimics at concentrations of 15 or 30 nM (Table S11).
Interestingly, induction of gluconeogenic enzymes G6pc, Pck1, and
Fbp1 by cAMP/dexamethasone was blunted after miR-205-5p trans-
fection (Table S11), consistent with the decrease in hepatic glucose
production. Among transcription factors and co-regulators, cAMP/
dexamethasone-induced Foxo1 levels (Table S11), as well as basal
Hnf6, Pparg, Foxo4, Srebp1c, and Crtc2 levels decreased (Table S11),
while Irs2 increased (Table S11). There were no changes in Gck and
Pklr, consistent with the lack of effects on lipogenesis (Table S11).
These ﬁndings are consistent with the dissociation between effects on
glucose vs. lipid production, and indicate that miR-205-5p preferen-
tially targets gluconeogenic genes either directly or through increased
insulin signaling.
3.6. miR-205-5p decreases fed glucose levels and improves
pyruvate tolerance in vivo
In view of the effect of miR-205 on hepatic glucose production in vitro
and its aberrant regulation in obese insulin-resistant mice, we tested
the function of miR-205-5p in vivo using gain- and loss-of-function
experiments. To phenocopy L-Foxo1,3a,4 mice, we injected AAV8-
TBG-miR-205-5p in lean mice, raising miR-205-5p 2-fold in the fas-
ted state, with no differences in the refed state (Figure 6A and S2AeB).
This increase did not alter weight (Figure S2C), and body composition
(Figures S2DeG). However, it did lower glucose excursion during
pyruvate tolerance tests (Figure 6B), suggesting an improvement in
gluconeogenesis as observed in vitro. It also lowered fed glycemia,
starting one week after injection (Figures S2HeI). Three weeks after
injection, random fed but not fasted or refed glucose levels were still
lower in mice with miR-205-5p gain-of-function (Figure 6C). Fasting
cholesterol (Figure 6D) and hepatic cholesterol content (Figure 6E)
were also lower, whereas plasma triglyceride (TG) and free fatty acids
(Figures S2JeK), as well as hepatic TG content did not change
(Figure S2L), consistent with the lack of effects on lipogenesis
observed in vitro. We also observed increased glycogen content in the
refed state compared to WT mice (Figure 6F). To study the mechanism
of these effects, we analyzed gene expression (Figure 6GeJ,
Figure S3). Gsk3b decreased and Irs1 increased during fasting,cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 53
Figure 3: miR-205-5p overexpression in primary hepatocytes activates Akt signaling. A-E, Representative immunoblot (A) and quantiﬁcation (B-D) of AKT (B), pAKT (C), and
pFOXO1 (T24) (D) levels in primary hepatocytes treated with vehicle or cAMP/dex in the presence or absence of 50 nM miR-205-5p mimics (n ¼ 7, 7, 6, and 3 per group in B-D,
respectively, from 2 mice). E, Ptpn2, Pten, Ship2, Phlpp1, Phlpp2 mRNA in primary hepatocytes in the presence or absence of 50 nM miR-205-5p mimics (n ¼ 8 per group from 2
mice). F-H, Representative immunoblot (F) and quantiﬁcation (G-H) of SHIP2 (G), or PTEN (H) levels in primary hepatocytes treated with vehicle or cAMP/dex in the presence or
absence of 50 nM miR-205-5p mimics (n ¼ 7 per group). I, Quantiﬁcation of FOXO1 levels in primary hepatocytes treated with vehicle or cAMP/dex in the presence or absence of
50 nM miR-205-5p mimics (n ¼ 7, 7, 6, and 3 per group, from 2 mice). J, Foxo1 mRNA in primary hepatocytes in the presence or absence of 50 nM miR-205-5p mimics (n ¼ 8
per group from 2 mice). K, Relative luciferase activity of 30UTR Foxo1 in primary hepatocytes transfected with miR-CTL vs. miR-205-5p mimics (50 nM). Secreted Gaussia
luciferase reporter gene activity was normalized to a secreted Alkaline Phosphatase reporter. Data are means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 4: Summary of miR-205-5p regulation of insulin signaling in vitro.whereas Gck and Insr increased in the refed state (Figure 6GeJ,
respectively), consistent with increased glycogen content. In contrast
with our in vitro data, we did not observed changes in gluconeogenic
genes (Figure S3), probably due to the modest increase in miR-205-5p
achieved in vivo, or to indirect mechanisms of mRNA control. Collec-
tively, overexpression of hepatic miR-205-5p in mice is consistent with
a decrease in glucose production.
Next, we performed loss-of-function experiments to test whether the
increased miR-205-5p expression observed in obese mice affectsFigure 5: miR-205-5p overexpression in primary hepatocytes decreases hepatic glu
novo lipogenesis (B, n ¼ 6 per group from 2 mice) in primary hepatocytes transfected with
2 mice) in primary hepatocytes transfected with varying concentrations of miR-CTL vs. m
MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.cominsulin sensitivity. We injected locked nucleic acids (LNA) antagomirs
targeting miR-205-5p in DIO mice, and killed the animals in the fasted
state 3 weeks after antagomir administration. Surprisingly, most of the
anti-miR-205-5p-treated mice did not gain weight during the ﬁrst two
weeks after injection compared to mice treated with anti-miR-CTL
(Figure 7A), even as they maintained similar body composition to
control mice (Figures S4AeE). This effect on weight confounds the
subsequent analyses and limits our ability to interpret these data.
Nonetheless, the animals displayed higher glucose excursions duringcose production. A-B, Glucose production (A, n ¼ 8 per group from 2 mice) and de
miR-CTL vs. miR-205-5p mimics (50 nM). C, Glucose production (n ¼ 8 per group from
iR-205-5p mimics. Data are means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
cess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 55
Figure 6: miR-205-5p overexpression in mice improve glucose homeostasis without increasing hepatic fat content. A, Hepatic miR-205-5p expression in C57Bl6 mice
after overexpression of miR-CTL vs. miR-205 (n ¼ 7 per group). B, PTT carried out after an overnight fast in miR-CTL vs. miR-205-injected mice (n ¼ 7 per group) 2 and 3 weeks
after injection, respectively. C, Glucose levels in ad libitum-fed (n ¼ 7 per group), overnight-fasted (n ¼ 7 per group) or 30-min- and 4-hr-refed (n ¼ 3 per group) mice injected
with miR-CTL vs. miR-205. D-E, Plasma and cholesterol levels in 12-hr-fasted (n ¼ 4 per group) and 4-hr-refed (n ¼ 3 per group) mice injected with miR-CTL vs. miR-205. F,
Hepatic glycogen content in 12-hr-fasted (n ¼ 4 per group) and 4-hr-refed (n ¼ 3 per group) miR-CTL vs. miR-205 mice. G-J, Hepatic Gsk3 (H), Irs1 (I) Gck (J) and Insr (K)
expression in 12-hr-fasted (n ¼ 4 per group) and 4-hr-refed (n ¼ 3 per group) mice injected with miR-CTL vs. miR-205. Experiments in A, and D-J were performed 25 days after
injection. Data are means  SEM. *P < 0.05, **P < 0.01, ***P < 0.001.
Original Articleglucose and pyruvate tolerance tests (Figure 7BeC). Three weeks after
injection, hepatic miR-205-5p decreased 3-fold compared to controls
(Figure 7E). 5-hr-fasting plasma triglycerides were lower (Figure 7F),
whereas glucose, cholesterol, and free fatty acids did not change
(Figure 7G, Figures S4FeG). There were no changes to hepatic
cholesterol, triglyceride, and glycogen content (Figures S4HeJ).
Finally, we analyzed changes in hepatic miR-205-5p targets
(Figure S5). Zeb1 mRNA, a known target of miR-205-5p, as well as
Fbp1 and Ship2 increased in mice treated with anti-miR-205-5p
(Figure 7HeJ), consistent with our in vitro data and the higher
glucose excursions during glucose and pyruvate tolerance tests.
Collectively, deletion of hepatic miR-205-5p in DIO mice prevented56 MOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. Tweight gain but worsened glucose and pyruvate tolerance. The former
effect may have blunted the latter.
4. DISCUSSION
FOXOs control gene transcription, but there is limited information on
the role of miRNA-mediated gene silencing in their functions. Here
we show that FOXOs modulate hepatic miRNA proﬁle, and that miR-
205-5p is an important target. We also show that miR-205-5p in-
creases in obese mice. miR-205-5p targets Foxo1 mRNA for
degradation, and deﬁnes a potential new mechanism of insulin
sensitization.his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: Effects of MiR-205-5p knock-down on glucose homeostasis in DIO mice. A, Differences in body weight among mice injected with control vs. miR-205 antagomirs 2
weeks after injection (n ¼ 10 per group). B-C, GTT (B, n ¼ 9 per group) and PTT (C, n ¼ 10 and 8, respectively) carried out after an overnight fast in control vs. miR-205 knock
down mice (n ¼ 10 per group) 14 and 18 days after injection, respectively. D, ITT carried out after a 5-hr-fast in control vs. miR-205 knock-down mice (n ¼ 9 per group) 3 weeks
after injection. E, Hepatic miR-205-5p expression in mice injected with control vs. miR-205 antagomirs in 5-hr-fasted (n ¼ 9 per group). F-G, Plasma triglyceride (F) and glucose
(G) levels in 5-hr-fasted (n ¼ 9 per group) control vs. miR-205 knock-down mice 25 days after injection. H-K, Hepatic Zeb1 (H), Fbp1 (I), and Ship2 (J) expression in 5-hr-fasted
(n ¼ 8 to 9 per group) control vs. miR-205 knock-down mice. Experiments in E-K were carried out 25 days after injection. Data are means  SEM. *P < 0.05, **P < 0.01,
***P < 0.001.Our data reveal a heretofore uncharacterized FOXOs-dependent miRNA
network. L-Foxo1,3a,4 mice display a blunted pattern of miRNA
regulation in response to fasting/refeeding. Thus, to the known func-
tion of FOXO to regulate expression of protein-coding genes, we add its
ability to regulate gene networks through hepatic miRNA. The effects of
FOXO are more pronounced in, but not limited to, the fasted state.
Whether this is due to indirect effects, or to residual FOXO function in
the refed state, remains to be investigated. Interestingly, a subset of
FOXO-dependent miRNA appears to play a homeostatic function on
metabolism and Akt signaling. We and others have described a ho-
meostatic loop between FOXO and Akt, whereby increased FOXO
function begets increased Akt function, and vice versa [23,44,45]. In
addition to previously proposed mechanisms [46], the present dataMOLECULAR METABOLISM 17 (2018) 49e60  2018 The Authors. Published by Elsevier GmbH. This is an open ac
www.molecularmetabolism.comindicate that miRNA can mediate this effect. Moreover, FOXO-regulated
miRNAs control Wnt and MAPK signaling. As these pathways are
known to interact with FOXO [47e50], the present data suggest that
miRNA-dependent regulation is a global component of FOXO signaling,
and effectively adds up to a second layer of FOXO control over
metabolic function.
MiR-205-5p showed profound expression changes in L-Fox1,3a,4
mice. miR-205-5p is often co-regulated with the tumor suppressor
miR-200 [51], which we also found to be inhibited by FOXO. However,
the mechanism by which FOXO inhibit miR-205-5p remains unclear.
We have not been able to show direct transcriptional regulation of miR-
205 by hepatic FOXO, raising the possibility that the effect is mediated
through longerange interactions, or by other transcription factors. It’scess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 57
Original Articlelikely that FOXOs prevent variations in hepatic miR-205-5p through an
indirect mechanism. Moreover, the reciprocal inhibition of FOXO and
miR-205-5p establishes a new homeostatic control mechanism. With
regard to metabolism, miR-205-5p reportedly regulates lipogenesis by
inhibiting glycogen synthase kinase 3b in adipose [52], and acyl-CoA
synthetase long-chain 1 (ACSL1) in hepatoma cells [43]. Here, we
report that miR-205 gain- or loss-of-function have no clear effect on
hepatic lipogenesis, whereas they affect glucose homeostasis, por-
tending a broader role for miR-205 in glycemic control. The early
postnatal death of miR-205 knockout animals (Table S10) [53] is
consistent with this hypothesis, possibly through impaired glucose
production. Regulation of glucose homeostasis by miR-205-5p may
depend on its ability to modulate FOXO1 by decreasing its mRNA levels
and through Akt activation.
Hepatic miR-205-5p levels also increase in non-diabetic obese mice.
These data are consistent with a previous report in mice showing that
hepatic miR-205-5p increases in diabetes-resistant, but not diabetes-
susceptible mice [36]. Indeed, in a limited cohort of human type 2
diabetics as well as in db/db mice with advanced diabetes, we also
observed a decrease of miR205 levels (data not shown). In line with the
improvement in glucose homeostasis induced in vitro and in vivo by
miR-205-5p overexpression, there appears to be an inverse correlation
between glycemia and hepatic miR-205 levels in the pathogenesis of
insulin resistance, similar to miR-320a and miR197 [54,55]. We pro-
pose that the role of miR-205-5p in non-diabetic obese individuals is to
protect against the development of hyperglycemia. A potential
mechanism linking it with FOXO in diabetes is that, when insulin levels
rise with insulin resistance, they inactivate FOXO, increasing miR-205.
As diabetes advances, hyperglycemia activates FOXO in liver [56],
suppressing miR-205. In summary, the present data delineate a
mechanism regulating insulin sensitivity through a FOXO-dependent
miRNA pathway. The data are consistent with the presence of a reg-
ulatory layer through miRNA that recapitulates the principal functions
of FOXO through regulation of gene expression.
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